BnR Summit 2025

Belt and Road Summit 2025- Deal-making

10 – 16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 4 September 2025

Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)

Haiyang Wang

CEO at Shanghai Haiju Biotechnology Co., Ltd.

Shanghai, China

About

HJ-462 features protein kinase inhibitors with ingenious molecular designs that avoid defects in drug metabolism within the body, resulting in excellent safety and remarkable efficacy(achieving 100% tumor regression in liver cancer, gastric cancer, and lung cancer models caused by MET amplification, effectively curing these conditions).

Project Location

  • China

Project Format

  • Private Project

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Feasibility Study Completed

Main Project Sector

  • Technology

Technology

  • Bio-Tech

Interested Format of Cooperation

  • Joint Venture
  • Minority Shareholdings
  • Open for Negotiation
  • R&D Cooperation

Preferred Financing Model

  • Equity
  • Open for negotiation

Previous Funding Stage

  • Seed & Pre-Series

Main Service(s) Required

  • Financial Services
  • Professional Services

Financial Services

  • Institutional Investment
  • Private Equity & Venture Capital

Professional Services

  • Business Valuation
  • Corporate Services
  • Market Entry Strategic Analysis

Organisation

Similar opportunities